EUCTR2013-003147-27-DE进行中（未招募）不适用
A PHASE 2, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) WITH THAT OF RANIBIZUMAB IN ADULT SUBJECTS WITH DIABETIC MACULAR EDEMA
Pfizer Inc 235 East 42nd Street, New York, NY 10017 US0 个研究点目标入组 200 人开始时间: 2013年12月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
- •2. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •3. Female subjects of non-childbearing potential =18 years and male subjects =18 years. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
- •4. Clinical diagnosis of diabetes mellitus (type 1 or type 2).
- •5. Stable medication for the management of diabetes (for those subjects on anti-diabetes medication) for at least 3 months before randomization and expected to remain stable during the study.
- •6. Serum HbA1c =10.5% at the screening visit.
- •7. Diabetic macular edema affecting the fovea in the study eye, consisting of central retinal thickness on OCT measuring 250 µm or more at the screening visit and a diagnosis of DME confirmed by fluorescein angiography.
- •8. Reduced visual acuity resulting from retinal thickening involving the center of the fovea and a BCVA, using ETDRS visual acuity protocol of 20/32 or worse (letter score of =78) and up to 20/320 or better (letter score =24) in the study eye at the screening visit.
- •9. Visual acuity score in the non-study eye of 20/400 or better (letter score of =19) at the screening visit.
- •10. Subjects who have not been treated with anti-angiogenic therapy, including pegaptanib sodium, bevacizumab, ranibizumab or aflibercept, or intra/peri-ocular steroids in either
- •eye within 3 months of the screening visit and who, from a clinical perspective, are considered suitable for the withholding of treatment for diabetic macular edema, including laser photocoagulation, for the duration of the study following enrolment (at least 90 days).
- •11. Ocular media and adequate pupillary dilation to allow good quality OCT and fundus photography.
- •12. If both eyes meet the inclusion criteria for this study, the most severely affected eye will become the study eye. If both eyes are affected equally, then the investigator and the
- •subject will select the study eye.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1. Subjects (subs) who are investigational site staff members directly
- •involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or subs who are Pfizer employees directly involved in the conduct of the trial. 2.
- •Participation in other studies involving investigational drug(s) (Ph. 1-4)
- •during study participation or within the prev. 60 days or 5 half-lives
- •preceding the 1st dose of study medication whichever is longer. 3. Other severe acute or chronic med or psychiatric condition or lab abnormality that may incr the risk associated with study participation or investigational product (IP) administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappro. for entry into this study. 4. Females of childbearing potential or who are pregnant or breastfeeding. 5. Males of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of IP. 6. Known history of HIV based on documented history with + serological test, or + HIV serological test at screening. 7. Any history of prev. untreated or current evidence of active or untreated latent infection with Mycobacterium tuberculosis (TB). 8. Family history of prolonged QT syndrome, or who themselves have a QTC >450 ms for males or >470 ms for females, a QRS >120 ms, or PR interval =300 ms, whether considered clinically significant or not, should not be incl. in study. Any clinically-significant ischemic changes as assessed by the investigator by 12-lead ECG at screening. The ECG should be repeated two more times and the av. of 3 QTc, QRS or PR values should be used to determine the subject's eligibility. QT should be corrected using Fridericia's correction. 9. Severely impaired renal function as defined by an eGFR of <30 mL/min/1.73m2 calculated using the CKDEPI eqn. at screening. 10. Any relevant, clinically-significant abnormalities on physical examination or clinically-significant lab tests, including subs with mod. liver function test abnormalities >1.5 times the upper limit of normal. 11. Pan retinal photocoagulation or macular photocoagulation performed in either eye within 3 mo. of the screening visit. 12. Any intraocular condition or prev. surgery in either eye that, in the opinion of the investigator, would either (a) likely require medical or surgical intervention during the 16 wk duration of the study to prevent or treat visual loss that might result
- •from that condition, or (b) if allowed to progress untreated, would likely contribute to loss of at least 2 ETDRS lines of BCVA over a 16 wk period, or (c) may affect macular edema or reduce visual acuity during the course of the study. 13. Ocular or peri-ocular infection in the study eye. 14. Cataract surgery in either eye within 60 days prior to study enrolment. 15. High risk proliferative diabetic retinopathy (PDR) in either eye. Inactive fibrosed neovascularization following pan retinal photocoagulation (PRP) laser therapy and non high risk PDR with no evidence of vitreous hemorrhage is permitted. 16. Structural damage to the center of the macula in either eye likely to preclude improvement in visual acuity following the resolution of macular edema, including but not limited to persistent DME involving the foveal center of more than 2 yrs in durati
研究者
相似试验
进行中（未招募）
1 期
Evaluate whether the clinical efficacy of PF-04634817 is non-inferior to ranibizumab, as measured by change from baseline in best corrected visual acuity after 12 weeks of treatment in subjects with diabetic macular edema (DME).Diabetic macular edema (DME)MedDRA version: 19.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2013-003147-27-CZPfizer Inc 235 East 42nd Street, New York, NY 10017 US200
进行中（未招募）
不适用
Evaluate whether the clinical efficacy of PF-04634817 is non-inferior to ranibizumab, as measured by change from baseline in best corrected visual acuity after 12 weeks of treatment in subjects with diabetic macular edema (DME).Diabetic macular edema (DME)MedDRA version: 17.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2013-003147-27-PLPfizer Inc 235 East 42nd Street, New York, NY 10017 US200
进行中（未招募）
不适用
Evaluate whether the clinical efficacy of PF-04634817 is non-inferior to ranibizumab, as measured by change from baseline in best corrected visual acuity after 12 weeks of treatment in subjects with diabetic macular edema (DME).PF-04634817 is a small molecule chemokine CCR2/5 receptor antagonist that is being developed for the treatment of diabetic nephropathy and diabetic macular edema.MedDRA version: 18.0Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853MedDRA version: 18.0Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2013-003147-27-HUPfizer Inc 235 East 42nd Street, New York, NY 10017 US200
进行中（未招募）
1 期
A PHASE 2, RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS INJECTIONS OF E10030 (ANTI-PDGF PEGYLATED APTAMER) GIVEN IN COMBINATION WITH LUCENTIS® IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION - REGRESSSubfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD)MedDRA version: 12.1Level: LLTClassification code 10064930Term: Age-related macular degenerationMedDRA version: 12.1Level: LLTClassification code 10067791Term: Wet macular degenerationEUCTR2010-018741-65-BEOPHTHOTECH CORPORATIO444
进行中（未招募）
不适用
A PHASE 2, RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS INJECTIONS OF E10030 (ANTI-PDGF PEGYLATED APTAMER) GIVEN IN COMBINATION WITH LUCENTIS® IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION - REGRESSSubfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD)MedDRA version: 14.1Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10064930Term: Age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2010-018741-65-HUOPHTHOTECH CORPORATIO444